465 results about "Osteoporosis" patented technology

The present application relates to animal bifidobacterium lactis Ca360 and its application. The present application also provides the application of animal bifidobacterium lactis in promoting the absorption and transport of minerals, improving osteoporosis, iron deficiency anemia and zinc deficiency. The animal bifidobacterium lactis of the present application can promote the absorption and transport of minerals, improve osteoporosis, iron deficiency anemia and zinc deficiency.

The invention provides a method and a device for constructing a female osteoporosis prediction model based on physical examination data. The construction method comprises the steps of obtaining a potential prediction variable set of female osteoporosis based on literature query; screening a sample set from the physical examination data; dividing the sample set into a training set and a verification set, and based on the preprocessed first training set, obtaining an intersection of variables screened by using a Boruta algorithm, an LASSO algorithm, a varSelRF algorithm and an SVM-RFE algorithm, and taking the intersection as a feature variable set of the osteoporosis prediction model; obtaining a second training set and optimizing the plurality of constructed initial prediction models by using the second training set to obtain a plurality of parameter tuning prediction models; and obtaining a test set, evaluating each parameter tuning prediction model by using the test set, and determining a female osteoporosis prediction model based on an evaluation result. The female osteoporosis can be predicted on the basis of eight conventional physical examination data, and the method has the advantages of high accuracy and medium sensitivity.

The invention relates to bifidobacterium animalis subsp. Lactis Ca360 and application thereof. The invention further provides application of the animal bifidobacterium subsp. Lactis in promoting absorption and transport of mineral substances and improving osteoporosis, iron-deficiency anemia and zinc deficiency. The bifidobacterium animalis subsp. Lactis disclosed by the invention can promote absorption and transport of mineral substances and improve osteoporosis, iron-deficiency anemia and zinc deficiency.

The invention provides a novel anti-human DKK-1 monoclonal antibody, aiming at solving the problems that osteoporosis antibody drugs developed in China at present are biosimilar drugs, and the existing antibody drugs also have certain defects, for example, Romosozumab is easy to cause cardiovascular adverse reactions, and DKK-1 antibody drugs aiming at osteoporosis do not appear on the market globally. According to the present invention, the rarely researched DKK-1 is adopted as the target spot to research the humanized DKK-1 antibody, such that the foundation is laid for the clinic and the effectiveness of the DKK-1 antibody, the treatment approach with the excellent effect is provided for the patient, and the problem of the lack of the innovation of the domestic antibody drug for treating osteoporosis can be hopefully solved.

A class of aromatic hydrocarbon receptor modulator compounds represented by the following formula I, or respective optical isomers, deuterated compounds, prodrugs or pharmaceutically acceptable salts thereof, and a preparation method therefor and the use thereof. The compounds can be used as aromatic hydrocarbon receptor modulators to regulate the activity of aromatic hydrocarbon receptors in vivo, which is of great significance for the treatment of related diseases such as immune diseases, inflammatory diseases, infections, skin diseases, osteoporosis, cancers and neurodegenerative diseases.

The invention provides a long-acting parathyroid hormone mutant, a fusion protein containing the same and application of the long-acting parathyroid hormone mutant, the amino acid sequence of the parathyroid hormone PTH34 mutant is shown as SEQ ID NO.1, and the parathyroid hormone PTH34 mutant is obtained through mutation of any one of the following mutations: L7A, N16S, M18H, L7A / N16S, L7A / M18H, N16S / M18H and L7A / N16S / M18H. The fusion protein formed after the mutant and HSA are connected through a connecting peptide is good in stability, long in half-life period and high in activity, and can be used for preparing the long-acting parathyroid hormone mutant. The traditional Chinese medicine composition can be well applied to preparation of medicines for treating osteoporosis.

The invention provides a traditional Chinese medicine composition for treating osteoporosis. The traditional Chinese medicine composition comprises rhizoma drynariae, eucommia ulmoides, fructus psoraleae, ligusticum wallichii, raw radix astragali, codonopsis pilosula, radix cyathulae and radix achyranthis bidentatae. The traditional Chinese medicine composition can be used for effectively treating osteoporosis, myopenia-osteoporosis and climacteric osteoporosis.

The invention provides application of an SNP genetic marker influencing chicken shin girth in chicken genetic breeding, and belongs to the technical field of chicken genetic breeding and biology.The SNP genetic marker influencing chicken shin girth comprises SCtag4, the SCtag4 corresponds to the 75909527th site of the physical position of a chromosome 4 of chicken reference genome bGa < l1 >. Mat.broi ler.GRCg7b version sequence information published in NCBI, belongs to the 8th intron sequence of a gene LDB2, and belongs to the technical field of chicken genetic breeding. The basic group is T or C. The SNP genetic marker is beneficial to heredity improvement of the shank girth, and is beneficial to improvement of the shank girth of laying hens and reduction of the incidence frequency of osteoporosis when being applied to genetic breeding of chickens, so that a high-quality laying hen variety is obtained.

The invention discloses an osteoporosis detection system based on nuclear magnetic resonance, and relates to the technical field of intelligent detection, the osteoporosis detection system comprises a pre-operation module, an image processing module, an analysis module and a precision module, an image segmentation model is trained to obtain an intervertebral disc image, the preprocessed image is segmented to obtain a region-of-interest image, and the region-of-interest image is obtained; and judging a first osteoporosis level of the region of interest, inputting the region of interest image to the expert platform to obtain a second osteoporosis level, and executing a second operation. Through cooperative work of the pre-operation module, the image processing module, the analysis module and the precision module, the detection precision and efficiency are improved, through the image segmentation model and the analysis module, more comprehensive osteoporosis evaluation is provided, an expert platform is introduced, the accuracy and reliability of a detection result are ensured, and the detection efficiency is improved. The MRI technology is used for osteoporosis detection, radiation exposure is avoided, and the method is a non-invasive and safe detection method.

The invention discloses a traditional Chinese medicine compound for preventing or treating osteoporosis and a preparation method, and relates to the field of traditional Chinese medicine, and the traditional Chinese medicine compound is prepared from the following raw materials in parts by weight: 20-30 parts of salted eucommia ulmoides, 15-20 parts of roasted herba epimedii, 15-20 parts of rhizoma drynariae, 15-30 parts of roasted astragalus membranaceus, 12-20 parts of angelica sinensis, 12-20 parts of fructus lycii and 6-9 parts of liquorice. The traditional Chinese medicine compound has a good effect of treating osteoporosis.

Disclosed herein are compounds of Formula (I) or pharmaceutically acceptable salts thereof: wherein R1 and R2 independently represent a hydrogen atom or a deuterium atom; r3'and R3 ''independently represent a hydrogen atom, a methyl group, a methoxyl group, a chlorine atom, a fluorine atom, or a cyano group; r4 represents a hydrogen atom or a fluorine atom; r5 and R5'independently represent a hydrogen atom or a fluorine atom; y represents-CH2-,-CH =,-CR9 =,-O-or-NH-wherein R9 represents a fluorine atom or a (C1-C3) alkyl group; represents a single bond or a double bond; p is 0 or 1; x represents-CH =,-N = or-CR ''= wherein R'' represents a (C1-C3) alkyl or halogen atom, a cyano group, or a (C1-C3) fluoroalkyl group; r7 independently represents a (C1-C3) alkyl group, a halogen atom, a cyano group, or a (C1-C3) fluoroalkyl group; n is 0, 1 or 2; and R6 represents a (C1-C6) alkyl group, said alkyl group being optionally substituted; r8 represents a hydrogen atom, a (C1-C3) alkyl group, a-CH2F group, a-CHF2 group, a-CF3 group, or a (C3-C4) cycloalkyl group. Further disclosed are processes for preparing the same, pharmaceutical compositions comprising the same and the compounds of formula (I) for use as inhibitors and degrading agents of estrogen receptors, in particular for use in the treatment of ovulation dysfunction, cancer, endometriosis, osteoporosis, benign prostatic hyperplasia or inflammation. # imgabs0 #

The invention belongs to the technical field of microbial function development, and particularly relates to lactobacillus plantarum YD666 and application of the lactobacillus plantarum YD666 in products for slowing down muscle atrophy and osteoporosis, the lactobacillus plantarum YD666 is preserved in the China Center for Type Culture Collection with the preservation number of CCTCC No: M 2025897, a preparation method of a lactobacillus plantarum YD666 bacterial suspension is provided, and the lactobacillus plantarum YD666 bacterial suspension can be used for preparing the lactobacillus plantarum YD666 bacterial suspension with the preservation number of CCTCC No: M 2025897. According to the lactobacillus plantarum YD666 and the application of the lactobacillus plantarum YD666 bacterial suspension in preparation of products for slowing down muscle atrophy and osteoporosis, the weight index of skeletal muscles of suspended tail rats can be increased by slowing down muscle weight loss caused by weightlessness; growth of muscle fibers is promoted, and the proportion of conversion from slow muscles to fast muscles is reduced, so that a weightlessness environment is resisted; the muscle movement contraction strength of the suspended tail rats is maintained, so that the application of relieving muscle atrophy under weightlessness is achieved, and the device is suitable for astronauts, crowds lack of movement and bedridden people who suffer from long-term illness and has wide market potential and application prospects.

The embodiment of the invention discloses a traditional Chinese medicine composition for treating osteoporosis, a traditional Chinese medicine preparation, a preparation method and application. The traditional Chinese medicine composition for treating osteoporosis is prepared from the following raw materials in parts by weight: 10 to 14 parts of radix rehmanniae praeparata, 10 to 14 parts of cortex eucommiae, 10 to 14 parts of radix dipsaci, 7 to 11 parts of fructus psoraleae, 7 to 11 parts of radix angelicae sinensis and 10 to 14 parts of radix paeoniae alba. The traditional Chinese medicine composition provided by the embodiment of the invention has a relatively good curative effect on osteoporosis.

The invention discloses application of pinoresinol diglucoside in increasing short-chain fatty acids in postmenopausal intestinal tracts and relieving postmenopausal intestinal inflammation, and belongs to the field of medicines. The pinoresinol diglucoside can regulate the abundance of bacteria such as Akecmann bacteria, other mycobacteria, parabacteroides and ruminococcus in intestinal tracts and promote the expression of short-chain fatty acids in the postmenopausal intestinal tracts, so that the postmenopausal intestinal inflammation and osteoporosis are relieved. The invention opens up a new clinical approach for treating diseases related to intestinal flora disorder of postmenopausal women.

The invention discloses a natural-source FFA4 receptor agonist and application thereof, relates to the technical field of medicines, and in particular relates to discovery of a natural compound action target spot which is a G protein coupled receptor FFA4. The FFA4 receptor agonist is medolamic acid, oleanolic acid and hederagenin and / or corresponding pharmaceutically acceptable salts, solvates or polymorphs and pharmaceutical compositions thereof, and the FFA4 receptor agonist is one of medolamic acid, oleanolic acid and hederagenin and / or pharmaceutically acceptable salts, solvates or polymorphs and pharmaceutical compositions thereof. An in-vitro cell target experiment shows that the pachymic acid, the oleanolic acid and the hederagenin are FFA4 agonists. Researches show that the FFA4 receptor is related to non-alcoholic fatty liver disease, stomach injury induced by non-steroidal anti-inflammatory drugs, osteoporosis, inflammatory bowel disease and other diseases, so that the agonist has potential medicinal application.

The invention belongs to the technical field of food and medicine, and relates to application of corn germ concentrated powder in improvement of osteoarthritis. The invention particularly relates to application of corn germ concentrated powder, namely corn antioxidant multienzyme, in preparation of medicines or health-care foods for treating rheumatoid arthritis and osteoporosis. In the corn germ concentrated powder, superoxide dismutase / (U / g) is greater than or equal to 8500, glutathione peroxidase / (U / g) is greater than or equal to 5000, and catalase / (U / g) is greater than or equal to 750. The corn germ concentrated powder can also be prepared by the following method: cleaning corn, germinating, adding water into the germinated corn, grinding and pulping, adding a settling agent into the corn steep liquor, standing, taking supernate, adding part of sodium ascorbate, performing temperature-controlled concentration, adding the rest sodium ascorbate and a stabilizer into the concentrated solution, and uniformly mixing to obtain the corn germ concentrated powder. And drying at controlled temperature, crushing, and mixing with a proper amount of silicon dioxide. The prepared corn germ concentrated powder has the effect of resisting rheumatoid arthritis.

A traditional Chinese medicine composition. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 7-13 parts of Acori Tatarinowii Rhizoma, 14-22 parts of Curcuma phaeocaulis, 14-22 parts of Cuscuta chinensis, 11-19 parts of oyster, 18-30 parts of Verbena officinalis, 12-19 parts of Schisandra chinensis, 14-22 parts of Poria cocos, 24-37 parts of Rhizoma Dioscoreae Hypoglaucae, 4-8 parts of licorice, and 4-9 parts of Indigo naturalis. The traditional Chinese medicine composition tonifies the kidney to consolidate the essence, and treats osteoporosis and prostatitis.

The invention relates to a beta-CTx binding antibody or an antigen binding fragment thereof, the beta-CTx binding antibody comprises a heavy chain variable region and a light chain variable region, and the heavy chain variable region and the light chain variable region contain HCDR and LCDR sequences; the invention also relates to corresponding isolated nucleic acid molecules, expression vectors and host cells. In addition, the invention also relates to a kit and a method for diagnosing osteoporosis in a subject.

The invention relates to the technical field of biomedical materials, in particular to a preparation process of novel composite bone cement with biological activity, which comprises the following steps: calcining calcium phosphate in a calcining furnace at 800-1000 DEG C for 3 hours, cooling to 20 DEG C, grinding the calcium phosphate by using a grinding machine until the diameter is less than 100 mu m, and drying to obtain the novel composite bone cement with biological activity. Calcium phosphate micro powder is obtained; by fusing the calcium phosphate, the nano-hydroxyapatite, the bioglass and the collagen, the material has a mechanical support function of an inorganic phase and biological activity of an organic phase, the nano-hydroxyapatite is extremely similar to human bone minerals and can promote osteoblast attachment and growth, and the collagen constructs a bionic microenvironment and accelerates new bone formation, so that the material can be used for treating osteoporosis. The bone repair efficiency is obviously improved.

The invention discloses a preparation method and application of nano-enzyme molecularly imprinted detection particles, a molecularly imprinted material is developed on the basis of a FeN3P nano-enzyme material, the molecularly imprinted material is fixed on filter paper to realize high-sensitivity and high-selectivity detection of 25-(OH) D3, real-time field detection of the molecularly imprinted material is realized by matching with a self-researched mobile phone APP: Visual Method, and the nano-enzyme molecularly imprinted detection particles have very high practical application value. Accurate data support is provided for early warning and personalized intervention of osteoporosis, community screening and long-term health management lack of 25 (OH) D3 can be promoted, and the method has important scientific value and social significance in reduction of the incidence rate of osteoporosis and optimization of medical resource allocation.

The invention belongs to the field of medicine, and discloses application of POCM-NP-coated A939572 in preparation of a medicine for treating osteoporosis, the POCM-NP-coated A939572 comprises osteoclast precursor cell membrane vesicles and NP-coated A939572 loaded on the osteoclast precursor cell membrane vesicles, and the NP-coated A939572 is PLGA (poly (lactic-co-glycolic acid)) nanoparticles entrapped with the NP-coated A939572. The POCM-NP-coated A939572 obtained by loading the nanoparticles loaded with the A939572 small molecule medicine into the osteoclast precursor cell membrane vesicles has the effect of relieving the osteoporosis, can inhibit osteoclast differentiation and can be used for preventing, treating and relieving the osteoporosis.

The invention provides a polyketone compound and application thereof in preparation of an osteoclast differentiation inhibitor, and relates to the technical field of marine natural products. The compound is obtained by separation and purification from a fermentation culture of a marine fungus talaromyces sp. GMIMD 02524 (the preservation number is GDMCC No. 66968), the compound is named as talaromyces furanone A, and the structure of the compound is as shown in the formula (I) in the specification. The compound can effectively inhibit RANKL-induced osteoclast differentiation by inhibiting an NF-kappa B signal channel in vitro, and has no obvious cytotoxicity at an effective concentration. Therefore, the compound talaromyfuranone A can be used for developing medicines for preventing and treating osteoclast-related osteolytic diseases such as osteoporosis and the like, and has a good application prospect.

The invention relates to a class of small molecule inhibitors of GPR68 / OGR1, a proton-sensing / stretch-sensing / sheer-stress-sending G-protein coupled receptor, and related receptors GPR4 and GPR65. These inhibitors are useful as a therapeutic for glioblastoma and other neoplasms, as a monotherapy or adjuvant, and also can be used as a treatment for other conditions, such as osteoporosis, inflammatory bowel disease, autoimmune and chronic inflammatory diseases such as multiple sclerosis and inflammatory pain syndromes, GERD, aspiration pneumonitis, bacterial and viral pneumonia, COPD, acute respiratory distress syndrome (ARDS), and COVID-19.

The invention provides application of polypeptide or related biological materials thereof in inhibition of osteoclast differentiation. The polypeptide with the amino acid sequence as shown in SEQ ID NO: 1 or related biological materials thereof can remarkably inhibit osteoclast differentiation, further effectively treat and / or prevent osteoporosis and is suitable for preparing products for treating and / or preventing osteoporosis.

Disclosed herein are compounds of Formula (I) or pharmaceutically acceptable salts thereof: wherein R1 and R2 independently represent a hydrogen atom or a deuterium atom; r3 represents a hydrogen atom or a-COOH group; r3'represents a hydrogen atom, a methyl group, a methoxy group, a chlorine atom, a fluorine atom, a cyano group, or a-COOH group; r3 ''represents a hydrogen atom, a methyl group, a methoxy group, a chlorine atom, a fluorine atom, or a cyano group; with the proviso that one but not both of R3 and R3'represents a-COOH group, and R3 and R3 'do not represent a hydrogen atom at the same time; r4 represents a hydrogen atom or a fluorine atom; r5 and R5'independently represent a hydrogen atom or a fluorine atom; y represents-CH2-,-CH =,-CR9 =,-O-or-NH-wherein R9 represents a fluorine atom or a (C1-C3) alkyl group; represents a single bond or a double bond; p is 0 or 1; x represents-CH =,-N = or-CR ''= wherein R'' represents a (C1-C3) alkyl or halogen atom such as fluorine or chlorine atom, cyano, or a (C1-C3) fluoroalkyl group such as trifluoromethyl; r7 independently represents a (C1-C3) alkyl group such as a methyl group, a halogen atom such as a fluorine atom, a cyano group, or a (C1-C3) fluoroalkyl group such as a trifluoromethyl group; n is 0, 1 or 2; and R6 represents an optionally substituted (C1-C9) alkyl group, and R8 in particular represents a (C1-C6) alkyl group. Further disclosed are processes for their preparation, pharmaceutical compositions comprising them and the compounds of formula (I) for use as inhibitors and degradation agents of estrogen receptors, in particular in the treatment of ovulation dysfunction, cancer, endometriosis, osteoporosis, benign prostatic hyperplasia or inflammation. # imgabs0 #

The invention discloses a preparation method and application of a multifunctional layered nanosheet. The biomimetic hydrogel is prepared through a hydrothermal method, folic acid (FA) is modified on the surface of the biomimetic hydrogel, and the biomimetic hydrogel has the capacity of targeted recognition of pro-inflammatory phenotype macrophages, has the biomimetic activity of multiple enzymes such as superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GPx) and can effectively remove ROS; meanwhile, a succinate dehydrogenase (SDH) inhibitor dimethylmalonic acid (DMM) is loaded in an intercalation mode of the nano material, SDH activity is inhibited in a slow release mode, ROS outbreak caused by mitochondrial reverse electron transfer (RET) is blocked from the source, then a mitochondrial autophagy pathway mediated by BNIP3-LC3B is started, and dynamic and steady state recovery of mitochondria is achieved. The system finally realizes macrophage mitochondrial function reconstruction, oxidation environment improvement and transfer of healthy mitochondria to osteoblasts, so that the osteogenic differentiation capability is recovered, and the effect of treating osteoporosis is achieved.

The invention belongs to the technical field of medical supplies, and particularly relates to a composition for improving perimenopausal symptoms. The feed consists of the following components in parts by weight: 400-700 parts of protein substances, 30-50 parts of fat substances, 120-170 parts of carbohydrate substances, 40-90 parts of dietary fiber substances, 30-80 parts of medicinal and edible substances, 2-6 parts of compound trace minerals, 50-95 parts of compound macro minerals, 3-5 parts of compound vitamins and 5-10 parts of blueberry powder. Wherein the protein substance is composed of whey protein, soybean protein and collagen peptide in a mass ratio of (7-12): (6.1-8.5): 1. According to the composition disclosed by the invention, the perimenopausal symptoms such as hectic fever, insomnia, osteoporosis, decrease of estrogen level, uterine atrophy and the like can be remarkably improved by accurately controlling the proportion of soybean protein and collagen peptide in protein.

The invention discloses a long-chain non-coding RNA (Ribonucleic Acid) and application thereof in regulating osteogenic differentiation of bone marrow mesenchymal stem cells. It is found that overexpression of long-chain non-coding RNA (lncRNA Gm20628) with the nucleotide sequence shown in SEQ ID NO.1 in bone marrow mesenchymal stem cells can effectively promote osteogenic differentiation of the bone marrow mesenchymal stem cells, and then bone defect repair of a mouse with skull injury is promoted. Therefore, the invention provides application of the expression promoter of the lncRNA Gm20628 in preparation for enhancing bone regeneration, repairing bone defects and treating osteoporosis and bone formation disorder related diseases. The method is not only beneficial to treatment of diseases related to the bone marrow mesenchymal stem cells, but also beneficial to construction of bone organs.

The invention provides an anti-osteoporosis milk-derived peptide YPSYG and application thereof, and a preparation method of the anti-osteoporosis milk-derived peptide YPSYG comprises the following steps: taking milk protein, firstly adding papain for enzymolysis, and then adding alkaline protease for enzymolysis to obtain the milk-derived peptide YPSYG. The milk-derived peptide with bone synthesis promoting activity can significantly improve bone biomechanical characteristics and bone microstructure, and can be used for preparing anti-osteoporosis drugs for treating osteoporosis. The milk-derived peptide YPSYG disclosed by the invention is convenient to synthesize, can be industrially produced, and has a good application prospect in the fields of medicines, cosmetics, health-care products and the like.

The invention discloses application of a compound with a benzo-aza structure in preparation of a medicine for inhibiting osteoclast formation, the structure of the compound is shown as a formula (1), and R substituent is one of H, OCH3, Br, F and i-Pr. Cell experiments prove that the compound with the benzo-aza structure has a remarkable inhibiting effect on RANKL-induced osteoclast differentiation and marker gene expression, can be used as a candidate medicine which is novel in structure and is used for inhibiting osteoclast formation, and is used for targeting osteoclast to treat osteoporosis related diseases.